Alliqua's SilverSeal Dressing Shown to Improve Surgical Wound Outcomes in Clinical Study
Study Results to be Presented at the Annual Meeting of the American Orthopaedic Foot & Ankle Society
LANGHORNE, Pennsylvania, (PRNewswire - July 18, 2013) - Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or the "Company") today announced the results from a post-marketing study to assess surgical wound outcomes in patients who have undergone foot and ankle surgery. In this study, Alliqua's SilverSeal(r) dressing was shown to have a lower incidence of incision complications, including infection, and a greater reduction in scar length compared to standard petroleum-based dressing. Study results are being presented at the annual meeting of the American Orthopaedic Foot & Ankle Society, which is being held in Hollywood, Florida July 17-20.
Stephen A. Brigido, DPM, director of the foot and ankle fellowship at the Coordinated Health Foot and Ankle Center and a primary investigator in the study, stated, "The results from this study are consistent with our preliminary findings reported earlier this year and indicate SilverSeal has potential to not only improve post-surgical incision healing but to reduce healthcare expenditures related to incision complications."
"The reduction in post-surgical incision complications and scarring shown in this study is a meaningful benefit for patients as well as for surgical centers and hospitals. We believe this study demonstrates that SilverSeal can be an effective tool in reducing complications such as infection, and will be useful in driving further adoption," added Philip Forman, Alliqua's EVP of clinical affairs.
In this study, patients who had undergone ankle and foot (including forefoot, midfoot or hindfoot) surgery were randomized to receive either SilverSeal or a standard petroleum-based dressing. Patients were monitored for three months following surgery to assess degree of scarring and the incidence of incision complications such as superf